Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Fiche publication
Date publication
février 2021
Journal
Clinical genitourinary cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Culine S, Fléchon A, Gravis G, Roubaud G, Loriot Y, Joly F, Barthélémy P, Assaf E, Mahammedi H, Beuzeboc P, Houédé N, Rolland F, Guillot A, Gross-Goupil M, Spano JP, Tartas S, Deblock M, Chevreau C, Serrate C, Manduzio H, Habibian M, Thézénas S, Allory Y
Lien Pubmed
Résumé
This study looked at whether epidermal growth factor receptor inhibition by the monoclonal antibody panitumumab could increase the efficacy of standard chemotherapy in advanced urothelial cancer. Results were disappointing, with higher toxicity and no improvement in efficacy in the combination arm.
Mots clés
Chemotherapy, Cisplatin, Epidermal growth factor receptor, Monoclonal antibody, Transitional cell carcinoma
Référence
Clin Genitourin Cancer. 2021 Feb 24;: